web analytics

BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 2019 World Conference on Lung Cancer (WCLC) in Barcelona, Spain (07 – 10 September 2019).
The two presentations will outline BerGenBio’s Phase II clinical trial (BGB008, NCT03184571) with bemcentinib and

Source: BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.